New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2013
11:49 EDTSODA, SPPI, MDRX, MELI, TSLAOptions with decreasing implied volatility: SPPI TSLA MDRX SODA MELI
News For SPPI;TSLA;MDRX;SODA;MELI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 29, 2015
10:25 EDTTSLAFirm says SpaceX explosion could hurt ViaSat
Subscribe for More Information
07:36 EDTSPPISpectrum coverage assumed with a Buy at H.C. Wainwright
Subscribe for More Information
06:56 EDTTSLATesla shares have 'substantially' more upside, says Credit Suisse
Credit Suisse analyst Dan Galves said Tesla shares are "much cheaper" now than they were when they hit their all-time high in September 2014, noting that near-term risks for the auto business have been lowered substantially and he sees "substantially" more upside as possible for the stock. Galves expects Tesla to deliver 11,000-11,500 vehicles in Q2, topping the company's estimate for 10,000-11,000 deliveries, and believes the lower-end Model S70D will lead to an uptick in deliveries in the second half of the year. Galves keeps an Outperform rating on the stock and raised the firm's price target for Tesla to $325 from $290, adding that he thinks valuations as high as about $400 are possible over the next 12-18 months.
June 26, 2015
16:00 EDTTSLAOptions Update; June 26, 2015
Subscribe for More Information
09:58 EDTTSLAChina to offer subsidies for new energy vehicles, People's Daily Online reports
Subscribe for More Information
08:11 EDTTSLATesla outlook positive, says Pacific Crest
After touring Tesla's factory, Pacific Crest says the company looks poised to meet its timetable for the launch of its Model x vehicle. The firm is more upbeat on the outlook for the company's energy storage business than it was previously, and thinks that the business could generate significantly more revenue than expected. The firm thinks the bear scenario of Q4 demand being too weak to support ramping production is unlikely to play out. It keeps an Overweight rating on Tesla.
June 25, 2015
16:00 EDTTSLAOptions Update; June 25, 2015
Subscribe for More Information
15:59 EDTTSLATesla China shipments slow again in May, IBD says
Tesla shipped only 163 Model S sedans to China in May, which was nearly double the prior month's total but down from the 414 units averaged in the past 12 months, said Investor's Business Daily, citing data released by JL Warren Capital. Reference Link
07:12 EDTTSLAAfter surveying 145 car owners, Jefferies raises Tesla price target
Jefferies analyst Dan Dolev raised his price target for Tesla shares to $360 from $350 after surveying 145 owners of the company's electric cars. The stock closed yesterday down $2.50 to $265.17. On average, owners were willing to pay 60% more for a Tesla, which suggests a much larger total addressable market when the lower priced Model III is introduced in 2017, Dolev tells investors this morning in a research note. Further, the survey highlighted "exceptional" brand loyalty, with 85% noting that their next car would be a Tesla, the analyst writes. Dolev upped his 2020 production estimate from 515K cars from 500K and keeps a Buy rating on Tesla.
06:00 EDTTSLATesla implied volatility of 29 at lower end of index mean range
Subscribe for More Information
June 24, 2015
09:35 EDTTSLAActive equity options trading on open
Subscribe for More Information
08:27 EDTMDRXAllscripts management to meet with Evercore ISI
Subscribe for More Information
07:02 EDTSPPISpectrum announces publication of Beleodaq data in Journal of Clinical Oncology
Spectrum Pharmaceuticals announced the publication of results from the pivotal BELIEF -- CLN-19 -- Study, which was selected as a Rapid Communication in the Journal of Clinical Oncology, the journal of the American Society of Clinical Oncology. The study, led by Dr. Owen O’Connor from the Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, NY, showed that monotherapy with Beleodaq produced complete and durable responses with manageable toxicity in patients with R/R PTCL across the major subtypes, irrespective of the number or type of prior therapies. Beleodaq, previously known as belinostat, is a histone deacetylase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. This indication is approved under accelerated approval based on tumor Response Rate and Duration of Response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. The primary endpoint of the BELIEF study was ORR as assessed centrally by an Independent Review Committee using the International Working Group criteria. The ORR in the 120 evaluable patients was 25.8%, including 13 Complete Responses and 18 Partial Responses. Secondary endpoints included a median DoR of 13.6 months by IWG criteria and 8.4 months to disease progression or death, with the longest ongoing patient at ≥36 months. The most common Grade 3/4 adverse events were anemia, thrombocytopenia, dyspnea, and neutropenia. No clinically relevant ECG changes were identified, and cardiovascular monitoring of ECGs is not required at baseline or during treatment. In this pivotal study, monotherapy with Beleodaq produced complete and durable responses with manageable toxicity in patients with R/R PTCL across the major disease subtypes, irrespective of the number or type of prior therapies and with a low incidence of Grade 3/4 thrombocytopenia.
June 23, 2015
11:39 EDTTSLAStocks with call strike movement; TSLA MU
Subscribe for More Information
June 22, 2015
16:00 EDTTSLAOptions Update; June 22, 2015
iPath S&P 500 VIX Short-Term Futures down 78c to 17.45. Option volume leaders: AAPL FB BAC CHK WMB BABA TWTR MU AMBA TSLA JPM
12:18 EDTTSLATesla volatility low after saying Model 3 'remains on schedule'
Subscribe for More Information
11:33 EDTTSLATesla off lows after saying Model 3 'remains on schedule'
Shares of Tesla are off their lows after the company told Bloomberg that production of the $35,000 Model 3 "remains on schedule." The comment comes after website Inside EVs reported yesterday that production of the lower priced model was pushed back to 2018. The Model 3 will reach full production in 2018, but production will start in 2017, the electric car maker told Bloomberg in an emailed statement. Shares of Tesla are down $2.51 to $260.00 in morning trading. The stock fell as low as $255.69 today.
11:17 EDTTSLATesla spokesperson says Model 3 'on schedule,' Bloomberg reports
Subscribe for More Information
10:06 EDTTSLATesla delays Model 3 launch to 2018, InsideEVs reports
Subscribe for More Information
09:48 EDTTSLATesla's need for cash and high stock price may be risky, WSJ reports
Tesla may be raising more money while it can after taking out a revolving credit agreement with several major banks, reports the Wall Street Journal. Current Finance Chief Deepak Ahuja's successor will likely make use of the new funding as the company's CapEx have often outpaced its operating cash flow. But if the Model X launch stumbles, the cash burn could exceed $1.5B and may end 2015 with less than $1B in available liquidity in a gloomier scenario. Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use